CPI Treatment Planning & Protocols 2 — Questions and Answers
Question 1: A protocol amendment changes the primary endpoint of an ongoing clinical trial. What is the MOST important immediate action the investigator must take?
- Continue the trial and apply the change at next patient visit
- Submit the amendment to the IRB and obtain approval before implementing (Correct answer)
- Notify all currently enrolled subjects and obtain updated consent before continuing
- Implement the change immediately to avoid protocol deviations
Correct answer: Submit the amendment to the IRB and obtain approval before implementing
Protocol amendments that alter primary endpoints require IRB review and approval before implementation.
Question 2: In a dose-escalation trial, the protocol specifies a 'DLT observation period' of 28 days. What does DLT stand for and why is this period critical?
- Drug Limitation Threshold — to assess long-term efficacy
- Dose-Limiting Toxicity — to evaluate safety before escalating to the next cohort (Correct answer)
- Drug Level Testing — to measure pharmacokinetic parameters
- Delayed Laboratory Testing — to confirm biomarker changes
Correct answer: Dose-Limiting Toxicity — to evaluate safety before escalating to the next cohort
DLT (Dose-Limiting Toxicity) observation periods ensure safety data are collected before exposing new subjects to higher doses.
Question 3: A subject enrolled in a cancer trial develops a grade 3 adverse event that is not listed in the protocol's dose modification table. What should the investigator do?
- Discontinue the subject from the trial immediately
- Use clinical judgment and document the rationale for any dose change
- Contact the sponsor's medical monitor for guidance before making any change (Correct answer)
- Follow standard of care guidelines and proceed without notifying the sponsor
Correct answer: Contact the sponsor's medical monitor for guidance before making any change
When protocol guidance is absent, the investigator should contact the sponsor's medical monitor to ensure consistent decision-making across sites.
Question 4: Which element is MOST essential when developing a treatment protocol for a Phase I first-in-human study?
- A broad patient population to maximize enrollment speed
- Detailed stopping rules and dose escalation criteria based on preclinical data (Correct answer)
- Inclusion of a placebo arm to establish a comparator
- Fixed dosing intervals regardless of toxicity findings
Correct answer: Detailed stopping rules and dose escalation criteria based on preclinical data
Phase I first-in-human studies require rigorous stopping rules and dose escalation criteria derived from preclinical safety data to protect subjects.
Question 5: A protocol mandates that study drug be administered within 30 minutes of a meal. A subject consistently takes the drug 60 minutes after eating. This represents a:
- Minor deviation that does not need documentation
- Protocol deviation that must be documented and reported per study procedures (Correct answer)
- Protocol violation requiring immediate subject discontinuation
- Acceptable variation within normal clinical practice
Correct answer: Protocol deviation that must be documented and reported per study procedures
Consistent departure from protocol-specified administration conditions is a protocol deviation requiring documentation and reporting.
Question 6: When a protocol specifies 'washout period' requirements before study drug initiation, the primary purpose is to:
- Allow subjects to recover psychologically from prior treatments
- Eliminate prior treatment effects that could confound study results or cause interactions (Correct answer)
- Ensure adequate time for informed consent documentation
- Meet regulatory timelines for subject enrollment
Correct answer: Eliminate prior treatment effects that could confound study results or cause interactions
Washout periods eliminate residual effects of prior treatments to reduce confounding and prevent drug-drug interactions.
Question 7: A randomized controlled trial uses a PROBE design. What does PROBE stand for?
- Prospective Randomized Open Blinded End-point (Correct answer)
- Placebo-controlled Randomized Observational Blinded Evaluation
- Parallel Randomized Open-label Blinded Efficacy
- Prospective Randomized Outcome-Based Evaluation
Correct answer: Prospective Randomized Open Blinded End-point
PROBE (Prospective Randomized Open Blinded End-point) uses open-label treatment assignment but blinded endpoint assessment to reduce bias.
CPI Treatment Planning & Protocols 2
A protocol amendment changes the primary endpoint of an ongoing clinical trial.
What is the MOST important immediate action the investigator must take?